ReviewCell cycle (Georgetown, Tex.)2016
A genetic view of laryngeal cancer heterogeneity.
Review in Cell cycle (Georgetown, Tex.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A Current Perspective of Two of the Most Aggressive Head and Neck Cancers: Pharyngeal and Laryngeal.Current oncology (Toronto, Ont.) · 2025Pooled it
- EPYC promotes laryngeal cancer carcinogenesis and angiogenesis by docking to VEGFR1: A novel therapeutic target.iScience · 2025Article
- Integration of Circulating miR-31-3p and miR-196a-5p as Liquid Biopsy Markers in HPV-Negative Primary Laryngeal Squamous Cell Carcinoma.Diseases (Basel, Switzerland) · 2025Article
- Arsenic trioxide regulates DYNAP through hsa-mir-573 and inhibits the proliferation of laryngeal cancer.Scientific reports · 2025Article
- Quality of Life of Patients Using Esophageal Speech after Total Laryngectomy: A Systematic Review Study.Journal of personalized medicine · 2024Review
- Computed tomography-based radiomic markers are independent prognosticators of survival in advanced laryngeal cancer: a pilot study.The Journal of laryngology and otology · 2024Article
- Clinical Behavior, Mutational Profile and T-Cell Repertoire of High-Grade Neuroendocrine Tumors of the Head and Neck.Cancers · 2023Article
- Differentially expressed genes related to lymph node metastasis in advanced laryngeal squamous cell cancers.Oncology letters · 2022Article
- VRK1 Predicts Poor Prognosis and Promotes Bladder Cancer Growth and MetastasisFrontiers in pharmacology · 2022Article
- DIAPH2, PTPRD and HIC1 Gene Polymorphisms and Laryngeal Cancer Risk.International journal of environmental research and public health · 2021Article
- An integrative microenvironment approach for laryngeal carcinoma: the role of immune/methylation/autophagy signatures on disease clinical prognosis and single-cell genotypes.Journal of Cancer · 2021Article
- Distinct Biomarker Profiles and Clinical Characteristics in T1-T2 Glottic and Supraglottic Carcinomas.The Laryngoscope · 2020Article
- Insight toward the MicroRNA Profiling of Laryngeal Cancers: Biological Role and Clinical Impact.International journal of molecular sciences · 2020Review
- Upper aerodigestive tract carcinoma: Development of a (epi)genomic predictive model for recurrence and metastasis.Oncology letters · 2020Article
- Dr. Jekyll and Mr. Hyde: MAP17's up-regulation, a crosspoint in cancer and inflammatory diseases.Molecular cancer · 2018Review
- Analysis of related factors of surgical treatment effect on 215 patients with laryngeal cancer.Experimental and therapeutic medicine · 2018Article
- Article
- Phosphorylation of gH2AX as a novel prognostic biomarker for laryngoesophageal dysfunction-free survival.Oncotarget · 2016Article
- Clinical, ultrasound and histopathological correlation of clinically N0 neck nodes in patients with cancers of the pharynx and larynx.Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologieArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
During the recent decades significant improvements in the understanding of laryngeal molecular biology allowed a better characterization of the tumor. However, despite increased molecular knowledge and clinical efforts, survival of patients with laryngeal cancer remains the same as 30 years ago. Although this result may not make major conclusions as preservation approaches were not broadly used until the time of database collection, it seems to be clear that there is still window for improvement. Although the cornerstone for laryngeal cancer eradication is to implement smoking cessation programs, survival progresses will be hopefully seen in the future. Introducing molecular biomarkers as predictive factors to determine which patients will benefit of preservation treatments may become one of the next steps to improve survival. Furthermore, the development of new therapeutic modalities joint to biomarkers to selectively apply such new therapy in these patients may help to define new modalities with improved survival. New inhibitors against Notch pathway, EGFR, VRK1 or DNA damage repair may become gold standard if we are able to identify patients that may benefit from them, either on survival or functional larynx preservation. It is the moment for an inflexion point on the way laryngeal cancer is clinically managed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.